Literature DB >> 16276273

Audit of trabeculectomy at a tertiary referral hospital in East Africa.

Joy Kabiru1, Richard Bowman, Mark Wood, Milka Mafwiri.   

Abstract

AIM: To audit medium-term results of trabeculectomy at a tertiary referral unit in east Africa.
METHODS: A retrospective review of the files of all patients who underwent trabeculectomy surgery at our hospital during the year 2001.
RESULTS: One hundred fifty-seven patients were included. Mean age was 61 years (SD = 12). Thirty-one patients (20%) were women; 120 of 145 (83%) eyes had cup/disc ratios of 0.8 or greater preoperatively. Intraoperative 5-fluorouracil (5FU) was used in 57 cases (36%). Mean follow-up was 8 months (0-28, SD = 7). Mean intraocular pressures (IOP) was 25 mm Hg (6-70, SD = 10) preoperatively, 11 mm Hg (0-32, SD = 5) at 2 weeks postoperatively, and 13 mm Hg (0-42, SD = 6) at latest follow-up. One hundred fifteen patients (73%) had intraocular pressure of 15 mm Hg or less at latest follow-up and 141 (90%) had intraocular pressure of 21 mm Hg or less. Twenty (13%) had restarted antiglaucoma medication during the follow-up period. Thirty-seven of 148 (25%) lost 2 lines of Snellen acuity or equivalent between preoperative measurement and latest follow-up. Early postoperative complications (usually leaking bleb or shallow anterior chamber with hypotony) occurred in 18 patients (12%) and this was associated with postoperative loss of 2 or more lines of Snellen acuity (OR = 1.11 95% CI 1.02-1.22, P= 0.02). Patients having had 5FU had lower (t = 3.11, P= 0.02) mean intraocular pressure at 2-month follow-up (12 mm Hg, SD = 5) than those who did not receive it (16 mm Hg, SD = 6) but there was no significant difference at later follow-ups. Men (mean 14 mm Hg, SD = 6) had higher (t = 2.71, P= 0.01) intraocular pressures at latest follow-up than women (mean 11 mm Hg, SD = 3).
CONCLUSIONS: The results of surgery compare well with other reported series. 5FU did not demonstrate significant benefit in terms of intraocular pressure lowering beyond 2 months postoperatively. Early postoperative hypotony should be avoided. The gender difference in intraocular pressure results has not previously been reported and deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16276273     DOI: 10.1097/01.ijg.0000185617.98915.36

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  How to manage a patient with glaucoma in Africa.

Authors:  Richard Jc Bowman; Subramaniam Kirupananthan
Journal:  Community Eye Health       Date:  2006-09

2.  Low-dose transscleral diode laser cyclophotocoagulation (TSCPC) as a potential single treatment for primary open-angle glaucoma (POAG) in Malawi?

Authors:  Markus Schulze Schwering; Petros Kayange; Volker Klauss; Khumbo Kalua; Martin S Spitzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-21       Impact factor: 3.117

3.  Intra-operative 5-FU in Glaucoma Surgery: A Nigerian Teaching Hospital Experience.

Authors:  Bernice O Adegbehingbe; H Onakpoya Oluwatoyin
Journal:  Middle East Afr J Ophthalmol       Date:  2008-04

4.  Is Beta Radiation Better than 5 Flurouracil as an Adjunct for Trabeculectomy Surgery When Combined with Cataract Surgery? A Randomised Controlled Trial.

Authors:  Kazim Dhalla; Simon Cousens; Richard Bowman; Mark Wood; Ian Murdoch
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

5.  Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial.

Authors:  Heiko Philippin; Einoti Matayan; Karin M Knoll; Edith Macha; Sia Mbishi; Andrew Makupa; Cristóvão Matsinhe; Vasco da Gama; Mario Monjane; Awum Joyce Ncheda; Francisco Alcides Mulobuana; Elisante Muna; Nelly Fopoussi; Gus Gazzard; Ana Patricia Marques; Peter Shah; David Macleod; William U Makupa; Matthew J Burton
Journal:  Lancet Glob Health       Date:  2021-10-13       Impact factor: 38.927

Review 6.  Glaucoma in developing countries.

Authors:  Ravi Thomas
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.